Halozyme Therapeutics (HALO) Stock Forecast & Price Target

$65.87 +1.30 (+2.01%)

Closing price 04:00 PM Eastern

Extended Trading

$66.76 +0.89 (+1.35%)

As of 05:14 PM Eastern

Compare

Halozyme Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 12 Analyst Ratings

Sell
1

Hold
5

Buy
6

Based on 12 Wall Street analysts who have issued ratings for Halozyme Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 1 has given a sell rating, 5 have given a hold rating, and 6 have given a buy rating for HALO.

Consensus Price Target

$79.11
20.10% Upside

According to the 12 analysts' twelve-month price targets for Halozyme Therapeutics, the average price target is $79.11. The highest price target for HALO is $95.00, while the lowest price target for HALO is $56.00. The average price target represents a forecasted upside of 20.10% from the current price of $65.87.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for HALO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Halozyme Therapeutics and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HALO Analyst Ratings Over Time

Type	Current Forecast 5/5/25 to 5/5/26	1 Month Ago 4/5/25 to 4/5/26	3 Months Ago 2/4/25 to 2/4/26	1 Year Ago 5/5/24 to 5/5/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$79.11	$78.56	$77.44	$62.89
Forecasted Upside	20.10% Upside	21.81% Upside	-0.62% Downside	3.74% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

HALO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HALO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Halozyme Therapeutics Stock vs. The Competition

Type	Halozyme Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.42	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	22.52% Upside	872.25% Upside	15.38% Upside
News Sentiment Rating	Positive News See Recent HALO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
4/29/2026	HC Wainwright 3 of 5 stars	Mitchell S. Not Rated	Boost Target	Buy	$90.00 ➝ $95.00	+48.76%
2/24/2026	Weiss Ratings Not Rated		Downgrade	Buy (B-) ➝ Hold (C)
2/19/2026	Benchmark 4 of 5 stars	Robert Wasserman 3 of 5 stars	Boost Target	Buy	$75.00 ➝ $90.00	+25.92%
2/19/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$65.00 ➝ $75.00	+3.60%
2/18/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brendan Smith Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
12/4/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Graig Suvannavejh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell	$56.00	-13.39%
11/4/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Outperform
11/4/2025	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Outperform	$91.00 ➝ $92.00	+38.97%
10/27/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$63.00 ➝ $65.00	-1.78%
10/20/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vikram Purohit Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$80.00 ➝ $79.00	+18.13%
Get the Latest News and Ratings for HALO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
10/14/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$70.00	+3.37%
10/6/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
1/10/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Catanzaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$52.00 ➝ $53.00	-0.24%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:12 PM ET.

HALO Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Halozyme Therapeutics is $79.11, with a high forecast of $95.00 and a low forecast of $56.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There is currently 1 sell rating, 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HALO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HALO, but not buy additional shares or sell existing shares.
: According to analysts, Halozyme Therapeutics's stock has a predicted upside of 20.10% based on their 12-month stock forecasts.
: Over the previous 90 days, Halozyme Therapeutics's stock had 1 upgrade and 1 downgrade by analysts.
: Halozyme Therapeutics has been rated by research analysts at Benchmark, HC Wainwright, TD Cowen, Weiss Ratings, and Wells Fargo & Company in the past 90 days.
: Analysts like Halozyme Therapeutics more than other "medical" companies. The consensus rating score for Halozyme Therapeutics is 2.42 while the average consensus rating score for "medical" companies is 2.30. Learn more on how HALO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Halozyme Therapeutics Recommendations

This page (NASDAQ:HALO) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Stock Forecast & Price Target

Halozyme Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

HALO Analyst Ratings Over Time

HALO Analyst Recommendations By Month

HALO Price Targets by Month

Halozyme Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

HALO Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Halozyme Therapeutics Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Halozyme Therapeutics (HALO) Stock Forecast & Price Target

Halozyme Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

HALO Analyst Ratings Over Time

HALO Analyst Recommendations By Month

HALO Price Targets by Month

Halozyme Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

HALO Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Halozyme Therapeutics Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools